Dr. Reddy's Laboratories Limited (NSE:DRREDDY)
1,298.00
-6.20 (-0.48%)
Sep 11, 2025, 12:31 PM IST
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 85.45B INR in the quarter ending June 30, 2025, with 11.37% growth. This brings the company's revenue in the last twelve months to 334.26B, up 15.86% year-over-year. In the fiscal year ending March 31, 2025, Dr. Reddy's Laboratories had annual revenue of 325.54B with 16.61% growth.
Revenue (ttm)
334.26B
Revenue Growth
+15.86%
P/S Ratio
3.25
Revenue / Employee
12.02M
Employees
27,811
Market Cap
1,085.57B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.77B |
Divi's Laboratories | 96.52B |
Cipla | 274.80B |
Apollo Hospitals Enterprise | 225.51B |
Mankind Pharma | 129.10B |
Zydus Lifesciences | 236.08B |
Fortis Healthcare | 80.94B |
Alkem Laboratories | 133.04B |
Dr. Reddy's Laboratories News
- 13 hours ago - Dr. Reddy’s Laboratories acquires STUGERON portfolio from Janssen Pharmaceutica for $50.5 million - Business Upturn
- 1 day ago - Nifty 50 top gainers today, September 9: Infosys, Dr. Reddy’s Laboratories, Wipro, Adani Ports and more - Business Upturn
- 2 days ago - Nifty 50 top losers today, September 8: Trent, Asian Paints, Dr. Reddy’s Laboratories, Nestle India and more - Business Upturn
- 4 days ago - Dr. Reddy’s Laboratories receives 7 USFDA observations at UK facility inspection - Business Upturn
- 14 days ago - Top stocks to buy today: Stock recommendations for August 28, 2025 - check list - The Times of India
- 20 days ago - Nifty 50 top gainers and losers today, August 21: Cipla, Dr. Reddy’s Laboratories, Bajaj Finserv among top performers - Business Upturn
- 23 days ago - Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. - GlobeNewsWire
- 4 weeks ago - Pharma sector stocks in focus: Citi flags competitive setback for Dr Reddy’s, Aurobindo in iron sucrose opportunity - Business Upturn